Altered expression of microRNA-223 in the plasma of patients with first-episode schizophrenia and its possible relation to neuronal migration-related genes.


Journal

Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664

Informations de publication

Date de publication:
11 11 2019
Historique:
received: 30 11 2017
accepted: 30 09 2019
revised: 10 09 2019
entrez: 13 11 2019
pubmed: 13 11 2019
medline: 6 8 2020
Statut: epublish

Résumé

Recent studies have shown that microRNAs (miRNAs) play a role as regulators of neurodevelopment by modulating gene expression. Altered miRNA expression has been reported in various psychiatric disorders, including schizophrenia. However, the changes in the miRNA expression profile that occur during the initial stage of schizophrenia have not been fully investigated. To explore the global alterations in miRNA expression profiles that may be associated with the onset of schizophrenia, we first profiled miRNA expression in plasma from 17 patients with first-episode schizophrenia and 17 healthy controls using microarray analysis. Among the miRNAs that showed robust changes, the elevated expression of has-miR-223-3p (miR-223) was validated via quantitative reverse transcription-polymerase chain reaction (qRT-PCR) using another independent sample set of 21 schizophrenia patients and 21 controls. To identify the putative targets of miR-223, we conducted a genome-wide gene expression analysis in neuronally differentiated SK-N-SH cells with stable miR-223 overexpression and an in silico analysis. We found that the mRNA expression levels of four genes related to the cytoskeleton or cell migration were significantly downregulated in miR-223-overexpressing cells, possibly due to interactions with miR-223. The in silico analysis suggested the presence of miR-223 target sites in these four genes. Lastly, a luciferase assay confirmed that miR-223 directly interacted with the 3' untranslated regions (UTRs) of all four genes. Our results reveal an increase in miR-223 in plasma during both the first episode and the later stage of schizophrenia, which may affect the expression of cell migration-related genes targeted by miR-223.

Identifiants

pubmed: 31712567
doi: 10.1038/s41398-019-0609-0
pii: 10.1038/s41398-019-0609-0
pmc: PMC6848172
doi:

Substances chimiques

MIRN223 microRNA, human 0
MicroRNAs 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

289

Références

Nature. 2014 Feb 13;506(7487):179-84
pubmed: 24463507
Nat Methods. 2015 Aug;12(8):697
pubmed: 26226356
Cell Mol Life Sci. 2012 Jan;69(1):89-102
pubmed: 21833581
J Clin Neurosci. 2015 Mar;22(3):570-4
pubmed: 25487174
Cytoskeleton (Hoboken). 2014 Jul;71(7):423-34
pubmed: 24931616
Curr Opin Genet Dev. 2011 Aug;21(4):491-7
pubmed: 21561760
Development. 1998 Dec;125(24):5055-67
pubmed: 9811589
Lancet. 2003 Sep 6;362(9386):798-805
pubmed: 13678875
Schizophr Bull. 2012 May;38(3):433-43
pubmed: 20732949
Hum Mol Genet. 2008 Apr 15;17(8):1156-68
pubmed: 18184693
BMC Genomics. 2008 Feb 25;9:91
pubmed: 18298816
Trends Cell Biol. 2007 Mar;17(3):118-26
pubmed: 17197185
Cell. 2005 Dec 2;123(5):819-31
pubmed: 16325577
PLoS One. 2011;6(6):e21635
pubmed: 21738743
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Mol Cell. 2004 Jul 23;15(2):185-97
pubmed: 15260970
Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18962-7
pubmed: 23112146
J Neurosci. 2008 Feb 20;28(8):1961-9
pubmed: 18287512
Biol Psychiatry. 2009 Jun 15;65(12):1006-14
pubmed: 19121517
Biol Psychiatry. 2015 Aug 15;78(4):231-9
pubmed: 25636176
Nucleic Acids Res. 2010 Jan;38(1):239-52
pubmed: 19850724
Cell Death Dis. 2015 Jan 29;6:e1622
pubmed: 25633291
Nature. 2010 Aug 12;466(7308):835-40
pubmed: 20703300
Mol Psychiatry. 2014 Jul;19(7):848-52
pubmed: 23917947
Genome Biol. 2007;8(2):R27
pubmed: 17326821
Biol Psychiatry. 2011 Jan 15;69(2):188-93
pubmed: 21183010
Curr Opin Cell Biol. 2011 Feb;23(1):47-54
pubmed: 21177090
Psychopharmacology (Berl). 2013 May;227(1):67-78
pubmed: 23318695
Nat Genet. 2011 Sep 18;43(10):969-76
pubmed: 21926974
Mol Psychiatry. 2010 Dec;15(12):1176-89
pubmed: 19721432
J Neurosci. 2009 Apr 1;29(13):4312-21
pubmed: 19339625
Neuromolecular Med. 2009;11(3):133-40
pubmed: 19458942
Schizophr Res. 2009 Apr;109(1-3):86-9
pubmed: 19264453
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Eur J Neurosci. 2002 Dec;16(12):2342-50
pubmed: 12492429
Int J Neuropsychopharmacol. 2007 Aug;10(4):557-63
pubmed: 17291371
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Am J Psychiatry. 2015 Nov 1;172(11):1141-7
pubmed: 26183697
Schizophr Res. 2013 Jan;143(1):116-24
pubmed: 23219075
Am J Med Genet B Neuropsychiatr Genet. 2015 Apr;168B(3):170-8
pubmed: 25656957
Science. 2004 Jan 2;303(5654):83-6
pubmed: 14657504
Cell Res. 2009 Jan;19(1):47-57
pubmed: 19114989
Nat Cell Biol. 2007 Jun;9(6):654-9
pubmed: 17486113
Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11650-5
pubmed: 21697510
J Neurosci. 2010 Mar 3;30(9):3508-17
pubmed: 20203211
BMC Med. 2004 Apr 28;2:13
pubmed: 15115547
J Psychiatr Res. 2012 Feb;46(2):198-204
pubmed: 22094284
Schizophr Res. 2010 Dec;124(1-3):183-91
pubmed: 20675101
Compr Psychiatry. 2016 Aug;69:216-24
pubmed: 27423364
Nat Rev Neurosci. 2015 Apr;16(4):201-12
pubmed: 25790865
J Mol Neurosci. 2015 Jul;56(3):562-71
pubmed: 25665552
Neuron. 2006 May 4;50(3):389-400
pubmed: 16675394
J Cell Sci. 2007 Nov 15;120(Pt 22):3941-51
pubmed: 17956944
Mol Biol Cell. 2012 Jan;23(1):176-87
pubmed: 22072788
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
pubmed: 18663219
Pediatr Nephrol. 2007 Oct;22(10):1703-10
pubmed: 17072652
Biol Psychiatry. 2011 Jan 15;69(2):180-7
pubmed: 21111402
PLoS One. 2014 Nov 24;9(11):e112745
pubmed: 25420024
Ann Hum Genet. 2013 Nov;77(6):504-12
pubmed: 23909765
Cell Death Dis. 2012 Aug 30;3:e381
pubmed: 22932723
Front Neurosci. 2015 Mar 10;9:74
pubmed: 25805966

Auteurs

Zhilei Zhao (Z)

Department of Neuropsychiatry, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.
International Research Center for Neurointelligence, The University of Tokyo, Bunkyo-ku, Tokyo, 113-0033, Japan.

Seiichiro Jinde (S)

Department of Neuropsychiatry, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan. jind-tky@umin.ac.jp.

Shinsuke Koike (S)

Department of Neuropsychiatry, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Mariko Tada (M)

Department of Neuropsychiatry, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Yoshihiro Satomura (Y)

Department of Neuropsychiatry, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Akane Yoshikawa (A)

Department of Neuropsychiatry, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Yukika Nishimura (Y)

Department of Neuropsychiatry, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Ryu Takizawa (R)

Department of Neuropsychiatry, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Akihide Kinoshita (A)

Department of Neuropsychiatry, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Eisuke Sakakibara (E)

Department of Neuropsychiatry, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Hanako Sakurada (H)

Department of Neuropsychiatry, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Mika Yamagishi (M)

Department of Neuropsychiatry, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Fumichika Nishimura (F)

Department of Neuropsychiatry, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Aya Inai (A)

Department of Child Neuropsychiatry, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Masaki Nishioka (M)

Department of Neuropsychiatry, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Yosuke Eriguchi (Y)

Department of Child Neuropsychiatry, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Tsuyoshi Araki (T)

Department of Neuropsychiatry, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Atsuhiko Takaya (A)

Department of Psychiatry, Fukui Kinen Hospital, Miura City, Kanagawa, 238-0115, Japan.

Chiemi Kan (C)

Department of Mental Health, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, 113-0033, Japan.

Maki Umeda (M)

Department of Mental Health, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Department of Public Health Nursing, Graduate School of Nursing Science, St. Luke's International University, Chuo-ku, Tokyo, 104-0044, Japan.

Akihito Shimazu (A)

Center for Human and Social Sciences, College of Liberal Arts and Sciences, Kitasato University, Sagamihara City, Kanagawa, 252-0373, Japan.

Hideki Hashimoto (H)

Department of Health Economics and Epidemiology Research, School of Public Health, the University of Tokyo, Bunkyo-ku, Tokyo, 113-0033, Japan.

Miki Bundo (M)

Department of Molecular Brain Science, Graduate School of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto City, Kumamoto, 860-8556, Japan.

Kazuya Iwamoto (K)

Department of Molecular Brain Science, Graduate School of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto City, Kumamoto, 860-8556, Japan.

Chihiro Kakiuchi (C)

Department of Neuropsychiatry, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Kiyoto Kasai (K)

Department of Neuropsychiatry, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.
International Research Center for Neurointelligence, The University of Tokyo, Bunkyo-ku, Tokyo, 113-0033, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH